机构:[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China[2]Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA[3]School of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing, China[4]Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[5]Department of Oncology, National Center of Gerontology, Beijing Hospital, Beijing, China[6]School of Pharmacy, Huazhong University of Science and Technology Tongji Medical College, Wuhan, Hubei, China[7]Department of Oncology and Hematology, The Second Hospital, Jilin University, Changchun, Jilin, China[8]Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Sardegna, Italy[9]Beijing University of Chinese Medicine, Beijing, China[10]Institute of Pathology, University Medicine of Greifswald, Greifswald, Germany[11]BIOPIC, Beijing Advanced Innovation Center for Genomics, and School of Life Sciences, Peking University, Beijing, China[12]Peking-T singhua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China[13]State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology Chinese Academy of Sciences, Beijing, China[14]Institute of Pathology, University of Regensburg, Regensburg, Germany[15]Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
This work is supported by National Key R&D Program of China (grant no
2018YFA0506903), National Science Foundation of China (grant no 91857108 and
81470839), National Science and Technology Major Projects for Major New Drugs
Innovation and Develop (grant no 2018ZX09711003-004-002), Tsinghua University
Initiative Scientific Research Program (grant no 20161080086) to LGC; NIH grants
R01CA136606 to XC; P30DK026743 for UCSF Liver Center; Grant from the Italian
Association Aainst Cancer (AIRC; grant no IG 19175) to DC; as well as National
Science Foundation of China (grant no 81872253) to LL.
第一作者机构:[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China[2]Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA
通讯作者:
通讯机构:[2]Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA[3]School of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing, China[4]Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China[8]Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Sardegna, Italy[*1]Department of Medical, Surgical, and Experimental Sciences, University of Sassari, via Padre Manzella 4, 07100 Sassari, Italy[*2]UCSF, 513 Parnassus Avenue, San Francisco, CA 94143, USA[*3]D410 Medical Science Building, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China 100084
推荐引用方式(GB/T 7714):
Li Che,Wenna Chi,Yu Qiao,et al.Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.[J].GUT.2020,69(1):177-186.doi:10.1136/gutjnl-2018-317581.
APA:
Li Che,Wenna Chi,Yu Qiao,Jie Zhang,Xinhua Song...&Ligong Chen.(2020).Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans..GUT,69,(1)
MLA:
Li Che,et al."Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.".GUT 69..1(2020):177-186